Financial Performance - Total operating revenue for Q1 2020 was ¥470,237,471.67, a decrease of 3.45% compared to the same period last year[13]. - Net profit attributable to shareholders was ¥56,678,189.03, an increase of 16.53% year-on-year[13]. - Net profit attributable to shareholders after deducting non-recurring gains and losses was ¥61,729,956.09, up 23.26% from the previous year[13]. - Basic earnings per share for Q1 2020 was ¥0.0588, an increase of 16.44% year-on-year[13]. - The company's total revenue for the reporting period was 470.24 million yuan, a decrease of 3.45% year-on-year, while the net profit attributable to the parent company increased by 16.53% to 56.68 million yuan[28]. - The total comprehensive income for the current period is CNY 60,218,832.36, compared to CNY 47,472,463.87 in the previous period, reflecting an increase of about 26.8%[86]. Cash Flow - Net cash flow from operating activities reached ¥298,324,893.36, representing a significant increase of 195.48% compared to the same period last year[13]. - Cash inflow from operating activities was 684,719,240.65, an increase from 627,566,253.19 in the previous period, representing a growth of approximately 9%[94]. - Cash outflow from operating activities totaled 386,394,347.29, compared to 526,604,528.38 in the previous period, showing a reduction of about 27%[97]. - The net cash flow from operating activities was 298,324,893.36, significantly higher than 100,961,724.81 in the previous period, marking an increase of approximately 195%[97]. - The company's cash and cash equivalents at the end of the period amounted to 593.19 million yuan, an increase of 60.33% compared to the end of the previous period, primarily due to cash inflows from operating activities[25]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,620,444,482.14, a 1.16% increase from the end of the previous year[13]. - Total liabilities amounted to ¥1,505,437,093.97, a marginal increase from ¥1,501,480,672.47, showing a growth of about 0.13%[65]. - Current liabilities rose to ¥1,382,414,607.79 from ¥1,366,397,253.92, representing an increase of approximately 1.93%[65]. - Owner's equity reached ¥2,115,007,388.17, up from ¥2,077,587,088.29, reflecting an increase of approximately 1.80%[68]. - The total amount of raised funds is 86,711,000 CNY, with 6.79% of the total amount having been changed in use[43]. Investments and Projects - The company has invested 31,438,410 CNY (78.60% of the committed investment) in the Nantong base new production line project, which is expected to be completed by July 31, 2020[43]. - The company has completed 100% of the investment in the Taicang base production line technical transformation project, which was due by August 31, 2018[43]. - The company signed a cooperation agreement with Fulongbao Pharmaceutical Technology Co., Ltd., investing 10 million yuan for a 20% equity stake, focusing on the production of pharmaceutical intermediates[29]. Risks and Challenges - The company faced risks related to the COVID-19 pandemic, which could impact operations, particularly in export markets, and plans to strengthen communication within the supply chain to mitigate these risks[33]. - The company is exposed to raw material price fluctuations, which may adversely affect operating performance; it aims to improve supplier management and dynamically manage the supply chain[34]. - The company primarily exports products and is subject to exchange rate risks; it will use financial instruments to mitigate these risks and manage foreign receivables[34]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,863[17]. - The company repurchased 5,650,400 shares, accounting for 0.59% of the total share capital, with a total transaction amount of 22.79 million yuan[29]. - The maximum transaction price for repurchased shares was 4.18 CNY per share, while the minimum was 3.82 CNY per share, with a total transaction amount of 22,793,971 CNY (excluding transaction fees)[37]. Compliance and Governance - The company has committed to avoid conflicts of interest and ensure strict compliance with promises made regarding share transfers and management activities[37]. - The company has not undergone an audit for the first quarter report[117]. - The company has implemented new revenue and leasing standards starting from 2020, with no retrospective adjustments made to prior comparative data[117].

Financial Performance - The company reported a total revenue of RMB 963,309,471 for the year 2019, with a cash dividend of RMB 0.1 per 10 shares to all shareholders[9]. - The company's operating revenue for 2019 was ¥1,664,423,796.64, a decrease of 7.82% compared to ¥1,805,648,808.19 in 2018[28]. - The net profit attributable to shareholders for 2019 was ¥81,643,737.20, down 49.17% from ¥160,624,232.89 in 2018[28]. - The net cash flow from operating activities for 2019 was ¥94,145,833.26, a significant decline of 69.42% compared to ¥307,852,991.62 in 2018[28]. - The basic earnings per share for 2019 was ¥0.0848, a decrease of 49.13% from ¥0.1667 in 2018[28]. - The total assets at the end of 2019 were ¥3,579,067,760.76, a decrease of 1.52% from ¥3,634,461,471.46 at the end of 2018[28]. - The company reported a net profit excluding non-recurring gains and losses of ¥114,690,626.90 for 2019, down 27.13% from ¥157,389,316.79 in 2018[28]. - The company achieved total revenue of CNY 166,442.38 million in 2019, a decrease of 7.82% compared to the previous year[57]. - The net profit attributable to shareholders was CNY 8,164.37 million, down 49.17% year-on-year[57]. Risk Management - The company faces risks including COVID-19 pandemic, industry risks, raw material price fluctuations, and exchange rate risks, which are detailed in the report[9]. - The company has established a comprehensive risk management framework to mitigate potential impacts from market volatility[9]. - The company is actively managing risks related to raw material price fluctuations and exchange rate volatility to maintain operational stability[166]. - Risks from the COVID-19 pandemic may impact operations, particularly in export markets, but the company has a solid customer base to mitigate these risks[163]. Research and Development - The company is focused on expanding its market presence and enhancing its product offerings through research and development initiatives[9]. - The company has invested CNY 10,682.39 million in R&D in 2019, representing 6.42% of its total revenue, maintaining a high level of investment in innovation[60]. - The company has developed key intermediates for major pharmaceutical companies, including Venetoclax and Turalio, supporting its growth in the pharmaceutical sector[58]. - The company has a total R&D area exceeding 10,000 square meters, with a dedicated Shanghai R&D center of approximately 5,000 square meters[50]. - The company has three main R&D centers, with the Shanghai Zhangjiang R&D center covering approximately 5,000 square meters[45]. - The number of R&D personnel increased to 357 in 2019, accounting for 30.20% of the total workforce, up from 24.12% in 2018[86]. Investment and Expansion - The company invested ¥30 million to establish an industrial investment fund focused on fine chemicals and biopharmaceuticals[44]. - The company signed a cooperation agreement to invest ¥10 million for an 18% stake in Yuchang Fine Chemical, enhancing its production capabilities for high-end pesticide intermediates[44]. - The company plans to invest in a new enzyme preparation and green research institute project to accelerate the development of its biocatalysis and high-end custom pharmaceutical intermediates[60]. - The company has decided to terminate the Taicang base production line upgrade project and use the remaining funds for permanent working capital[126]. - The company plans to delay the Nantong base expansion project to July 2020 and the Binhai base expansion project to May 2020 due to regulatory impacts from a chemical plant explosion[126]. Dividend Policy - The company proposed a cash dividend of 0.1 yuan (including tax) for every 10 shares based on a total share capital of 963,309,471 shares as of December 31, 2019[176]. - The total cash dividend amount for 2019 was 9,633,094.71 yuan, which accounted for 100% of the distributable profit of 12,189,240.73 yuan[173]. - The company distributed a cash dividend of 0.5 yuan (including tax) for every 10 shares for the first half of 2019, approved by the shareholders' meeting[175]. - The cash dividend for 2018 was 86,697,852.39 yuan, representing 53.98% of the net profit attributable to ordinary shareholders[176]. - The cash dividend for 2017 was 38,532,378.84 yuan, which accounted for 52.66% of the net profit attributable to ordinary shareholders[176]. - The company has consistently maintained a clear and transparent cash dividend policy, aligning with its articles of association and shareholder resolutions[172]. Corporate Governance - The company’s financial report has been verified for accuracy and completeness by its board and management[8]. - The company has appointed China International Capital Corporation as its sponsor for continuous supervision during the reporting period[27]. - The independent directors have fulfilled their responsibilities and ensured the protection of minority shareholders' rights during the dividend distribution process[172]. - The company has maintained a continuous relationship with its accounting firm for six years, with an audit fee of 900,000 RMB[192]. - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[186]. - The company faced a criticism for delayed information disclosure, resulting in a public reprimand on October 24, 2019[197]. Subsidiaries and Market Position - The overall performance of subsidiaries significantly impacts the company's financial results, with varying profitability across different entities[144][145][148][149][151][154]. - The company is focused on expanding its market presence and enhancing its product offerings through research and development initiatives[144][145][148][149][150][151][154]. - Future outlook includes potential mergers and acquisitions to strengthen market position and diversify product lines[144][145][148][149][150][151][154]. - The company has signed a significant contract worth RMB 3.5 billion for the key intermediate of the patented product, which is expected to stabilize sales revenue and cash flow in 2020[161]. - Yayben Chemical plans to strengthen its pesticide business while leveraging its advantages in biotechnology to enhance its pharmaceutical business layout, aiming for industrialization and scale development[159].

Financial Performance - Operating revenue for the reporting period was approximately ¥408.81 million, representing a decrease of 16.29% year-on-year[8]. - Net profit attributable to shareholders of the listed company was approximately ¥43.68 million, a decline of 57.92% compared to the same period last year[8]. - Basic earnings per share for the reporting period were ¥0.0453, a decrease of 57.95% compared to the previous year[8]. - The company's operating cash flow for the period was CNY 60.80 million, a decrease of CNY 127.24 million or 67.67% compared to the same period last year, attributed to increased cash payments for goods and services[21]. - The company's financial expenses for the period were CNY 253.92 million, an increase of CNY 279.72 million or 1084.35% compared to the same period last year, primarily due to exchange rate fluctuations and interest on loans[21]. - The company's income tax expense for the period was CNY 5.18 million, a decrease of CNY 15.63 million or 75.11% compared to the same period last year, due to production and sales impacts from the shutdown of a subsidiary[21]. - The company's total operating revenue for Q3 2019 was CNY 408,814,277.11, a decrease of 1.1% compared to CNY 415,034,545.06 in the same period last year[45]. - Net profit for Q3 2019 was CNY 48,636,927.91, slightly down from CNY 49,456,450.11 in Q3 2018[47]. - The net profit for the third quarter of 2019 was CNY 63,297,648.91, a decrease of 51.1% compared to CNY 129,639,451.11 in the same period last year[57]. - The total profit for the quarter was CNY 68,476,728.80, down 54.4% from CNY 150,444,423.64 year-over-year[57]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥3.45 billion, a decrease of 5.13% compared to the end of the previous year[8]. - Net assets attributable to shareholders of the listed company were approximately ¥1.93 billion, down 2.91% from the previous year[8]. - The cash balance at the end of the period was CNY 313.22 million, a decrease of CNY 282.15 million or 47.39% compared to the end of the previous year, primarily due to cash outflows from investment activities of CNY 117.92 million and financing activities of CNY 76.70 million[21]. - The balance of prepaid accounts at the end of the period was CNY 108.68 million, an increase of CNY 57.24 million or 111.28% compared to the end of the previous year, mainly due to advance inventory preparations for the fourth quarter[21]. - The company's long-term borrowings at the end of the period were CNY 61.00 million, a decrease of CNY 79.25 million or 56.51% compared to the end of the previous year, due to loan repayments[21]. - Total liabilities decreased to CNY 1,416,561,111.98 from CNY 1,556,178,255.79[35]. - The company's total assets decreased to CNY 2,176,201,141.77 from CNY 2,356,763,954.94 in the previous year[44]. - Total liabilities decreased to CNY 536,115,417.82 from CNY 588,105,112.47 year-on-year[42]. - The company's total assets were reported at CNY 3,447,898,174.17, down from CNY 3,634,461,471.46[34]. - The equity attributable to shareholders decreased to CNY 1,928,800,273.77 from CNY 1,986,526,109.98[37]. Cash Flow - The net cash flow from operating activities was not disclosed, but it decreased by 67.67% compared to the previous year[8]. - Cash inflow from financing activities was CNY 671,860,211.86, an increase from CNY 595,900,382.40 in the previous period, reflecting a growth of approximately 12.5%[66]. - Cash outflow from investing activities totaled CNY 328,658,769.11, compared to CNY 460,797,498.67 in the previous period, indicating a decrease of approximately 28.7%[66]. - Net cash flow from financing activities was negative CNY 76,696,325.65, worsening from negative CNY 64,567,847.68 in the previous period[67]. - The company reported a cash and cash equivalents balance of CNY 236,234,993.28 at the end of the period, down from CNY 613,513,935.08[67]. - The company reported a net cash increase from operating activities of CNY 147,247,318.66, significantly higher than CNY 18,169,455.54 in the previous period[68]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,454[13]. - The company announced a cash dividend of CNY 0.5 per 10 shares for the fiscal year 2018, approved on May 10, 2019, and distributed on June 20, 2019[27]. - For the first half of 2019, the company proposed a similar cash dividend of CNY 0.5 per 10 shares, approved on September 10, 2019, and distributed on September 20, 2019[27]. Research and Development - Research and development expenses for Q3 2019 were CNY 23,082,378.63, up from CNY 19,648,630.73 in the same period last year[45]. - Research and development expenses increased to ¥2,552,061.38 from ¥1,972,298.87, reflecting a focus on innovation[53]. - Research and development expenses were CNY 6,612,276.15, a decrease of 22.8% compared to CNY 8,575,808.00 in the previous year[62].

Financial Performance - Total revenue for the first half of 2019 was CNY 691,353,686.55, a decrease of 23.12% compared to CNY 899,226,138.32 in the same period last year[26]. - Net profit attributable to shareholders was CNY 6,836,442.87, down 91.06% from CNY 76,462,202.12 year-on-year[26]. - Net cash flow from operating activities was CNY 142,991,469.11, a decline of 50.07% compared to CNY 286,379,408.61 in the previous year[26]. - Basic and diluted earnings per share were both CNY 0.0071, reflecting a decrease of 91.06% from CNY 0.0794 in the same period last year[26]. - Weighted average return on equity was 0.34%, down from 3.99% year-on-year, indicating a significant decline in profitability[26]. - Operating profit was RMB 63.76 million, down 31.66% year-on-year, while total profit decreased by 79.72% to RMB 18.92 million[46]. - The company’s financial expenses surged by 950.90% due to foreign exchange fluctuations, impacting overall profitability[54]. - The company’s cash flow from operating activities decreased by 50.07% to RMB 142.99 million, primarily due to increased cash payments for goods and services[54]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,353,362,255.92, a decrease of 7.73% from CNY 3,634,461,471.46 at the end of the previous year[26]. - Net assets attributable to shareholders were CNY 1,938,073,176.03, down 2.44% from CNY 1,986,526,109.98 at the end of the previous year[26]. - The company's accounts receivable decreased by 46.67% to approximately RMB 269.43 million, attributed to a decline in sales[56]. - The company's total assets included cash and cash equivalents of approximately RMB 468.64 million, representing 13.98% of total assets, down from 21.90% the previous year[62]. - The company's short-term borrowings increased by 6.00% to approximately RMB 749.66 million, primarily due to increased working capital loans[62]. - The company's long-term borrowings decreased by 49.38% to approximately RMB 71 million, primarily due to loan repayments[58]. Dividends and Shareholder Information - The company plans to distribute a cash dividend of CNY 0.5 per 10 shares, totaling CNY 48,165,474.35 based on 963,309,471 shares[9]. - The total number of shares for the dividend distribution is based on 963,309,471 shares[114]. - The distributable profit for the period is reported at 275,010,974 yuan[114]. - The total number of common shareholders at the end of the reporting period was 13,478, with a significant shareholder, Alashankou Yaben Venture Capital Co., Ltd., holding 31.12% of shares, totaling 299,829,707 shares[178]. - Wang Xinya, a natural person shareholder, holds 8.72% of shares, amounting to 84,000,350 shares[180]. - The top ten unrestricted common shareholders collectively hold 576,000,000 shares, with the largest shareholder holding over 299 million shares[184]. Strategic Initiatives and Market Position - The company operates four production bases in China and Malta, enhancing its production capacity and supporting sustainable development[37]. - The company has established strategic partnerships with leading firms in the agrochemical and pharmaceutical sectors, including Bayer and Roche, to expand market share and improve profitability[38]. - The company has a strong focus on R&D, with over a hundred national patents and core technologies in asymmetric synthesis and biocatalysis, ensuring high product stability and reliability[41]. - The company has adopted a "technology + environmental protection" dual-driven strategy, acquiring 51% of Ailwan, a company specializing in organic waste treatment[38]. - The company emphasizes a customized production model, allowing for high unit profit margins and stable customer relationships[36]. - The company is positioned to benefit from the growing market potential in the kitchen waste treatment sector, leveraging its advanced technology and equipment[53]. Environmental Compliance and Safety - The company is classified as a key pollutant discharge unit, with wastewater COD emissions at 186 mg/L[147]. - The total wastewater discharge was 4.254 tons per year, with a permitted total of 15.847 tons per year[147]. - The company has implemented continuous emissions monitoring for various pollutants, including VOCs and nitrogen oxides[155]. - The wastewater treatment facilities are compliant with the local environmental discharge standards, ensuring sustainable operations[155]. - The company aims to reduce its annual VOC emissions to align with regulatory requirements[155]. - The company experienced a safety incident in February 2019, leading to a production halt until June 27, 2019[167]. - The company’s subsidiary, Jiangsu Jianong, is currently under production suspension due to strict safety regulations following a chemical explosion incident in the region[167]. Future Outlook and Risks - Future outlook remains uncertain due to market conditions and policy environment, emphasizing the need for risk awareness among investors[8]. - The company faces various risks that may impact future performance, as detailed in the report[9]. - The company is actively managing foreign exchange risks by improving accounts receivable management and utilizing financial products[110]. - The company plans to strengthen its technology research and development to enhance core competitiveness and mitigate industry risks[109]. - The company aims to expand its market presence and reduce reliance on the North American market due to trade tensions[109].

Financial Performance - Total revenue for the first quarter was CNY 487,024,991.82, a decrease of 1.51% compared to CNY 494,488,955.58 in the same period last year[10] - Net profit attributable to shareholders increased by 31.94% to CNY 48,640,300.91 from CNY 36,865,897.81 year-on-year[10] - Net profit excluding non-recurring gains and losses rose by 38.29% to CNY 50,079,662.27 compared to CNY 36,214,097.81 in the previous year[10] - Basic earnings per share rose by 31.85% to CNY 0.0505 from CNY 0.0383 in the same period last year[10] - Operating profit increased to RMB 67.65 million, up 56.26% year-on-year, driven by improved product gross margins and an increase in the proportion of pharmaceutical products[26] - The company reported a significant increase in management expenses to CNY 29,731,656.51, up 94.7% from CNY 15,275,182.74, which may impact future profitability[72] - The total comprehensive income for the period was CNY 47,472,463.87, compared to CNY 43,111,329.96 in the previous year, showing overall growth[76] Cash Flow and Investments - Net cash flow from operating activities increased by 32.97% to CNY 100,961,724.81 from CNY 75,929,153.85 year-on-year[10] - The cash flow from financing activities resulted in a net outflow of -2,551,272.38 CNY, contrasting with a net inflow of 22,383,215.15 CNY in the same period last year[85] - The company reported a cash outflow from investing activities of 80,811,672.12 CNY, compared to 627,120,850.89 CNY in the previous year, indicating a reduction in investment expenditures[85] - The company has invested 225.96 million CNY in the current quarter, with a cumulative investment of 834.03 million CNY[42] - The company reported a net cash flow from investing activities of -$5,095,232.30, compared to -$204,013,801.86 in the previous period, showing a decrease in cash outflow[90] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,566,308,637.56, a decrease of 1.88% from CNY 3,634,461,471.46 at the end of the previous year[10] - Total current assets decreased from CNY 1,629,395,514.87 to CNY 1,520,093,412.86, a decline of approximately 6.7%[60] - Total liabilities decreased from CNY 1,556,178,255.79 to CNY 1,440,552,958.01, a decrease of about 7.4%[62] - Long-term borrowings at the end of the period were RMB 71 million, a decrease of 49.38% compared to the previous period, due to repayment of long-term loans[23] - The company's cash and cash equivalents decreased from CNY 81,023,120.83 to CNY 31,640,777.65, a decline of about 60.9%[65] Shareholder Information - Net assets attributable to shareholders increased by 2.16% to CNY 2,029,357,703.11 from CNY 1,986,526,109.98 at the end of the previous year[10] - The total number of ordinary shareholders at the end of the reporting period was 12,580[14] - The total equity of the company was CNY 1,753,711,153.53, down from CNY 1,768,658,842.47 in the previous year[71] Research and Development - Research and development expenses for the period were RMB 24.83 million, an increase of 101.21% year-on-year, reflecting the company's strengthened R&D investment[24] - R&D expenses rose significantly to CNY 24,833,569.53, up 101% from CNY 12,342,338.92 year-over-year, indicating a strong focus on innovation[72] Market and Operational Strategy - The company plans to actively communicate with relevant authorities to ensure the timely resumption of production at its Nantong base, which was temporarily halted due to a safety incident[26] - The company is facing risks from macroeconomic fluctuations, particularly due to trade tensions and exchange rate instability, which could impact its export-oriented business[29] - The company plans to enhance its market development efforts in Europe and domestically to mitigate potential risks associated with macroeconomic changes[33] - The company aims to strengthen its technological research and development to maintain its market share and improve overall profitability amidst industry risks[33] Compliance and Governance - The company has not undergone an audit for the first quarter report, which may affect investor confidence[99] - The company has made a commitment to act in concert regarding decisions on relevant matters during the holding of shares[41]

Financial Performance - The company's operating revenue for 2018 was CNY 1,805,648,808.19, representing a year-on-year increase of 49.50% compared to CNY 1,207,829,069.32 in 2017[21]. - The net profit attributable to shareholders for 2018 was CNY 160,624,232.89, a significant increase of 119.52% from CNY 73,169,190.21 in 2017[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 157,389,316.79, up 121.66% from CNY 71,004,787.27 in 2017[21]. - The company's total assets at the end of 2018 reached CNY 3,634,461,471.46, marking a 14.14% increase from CNY 3,184,229,174.08 at the end of 2017[21]. - The basic and diluted earnings per share for 2018 were both CNY 0.1667, representing a 95.43% increase from CNY 0.0853 in 2017[21]. - The company achieved total revenue of 1,805.65 million yuan, a year-on-year increase of 49.50%[44]. - Operating profit reached 222.93 million yuan, up 186.77% compared to the previous year[44]. - Net profit attributable to shareholders was 160.62 million yuan, reflecting a growth of 119.52% year-on-year[44]. - R&D expenses amounted to 107.25 million yuan, an increase of 33.92% from the previous year, representing 5.94% of total revenue[44]. Cash Dividends - The company reported a profit distribution plan, proposing a cash dividend of 0.50 RMB per 10 shares (tax included) based on a total of 963,309,471 shares[7]. - The total cash dividend amount for 2018 is 48,165,473.55 yuan, which accounts for 100% of the distributable profit[127]. - In 2018, the cash dividend amount (including tax) was CNY 48,165,473.55, representing 29.99% of the net profit attributable to ordinary shareholders[131]. - The cash dividend amount in 2017 was CNY 38,532,378.84, which accounted for 52.66% of the net profit attributable to ordinary shareholders[131]. - In 2016, the cash dividend amount was CNY 21,478,980.72, exceeding the net profit attributable to ordinary shareholders by 132.54%[131]. Strategic Initiatives - The company is focused on expanding its market presence and enhancing its product offerings through new technologies and research and development initiatives[7]. - The company completed the registration of 51% equity in Ailwan, which provides engineering technology services for organic waste treatment, aligning with the company's dual-driven strategy of "technology and environmental protection"[32]. - The company has established strategic partnerships with leading agricultural chemical companies such as FMC, Bayer, and Corteva for joint research and development of new pesticide products[33]. - The company plans to deepen cooperation with multinational giants like Corteva and Bayer to accelerate the launch of over 10 new high-value pesticide products[119]. - The company aims to optimize its management system and integrate resources across its subsidiaries to enhance competitiveness in the pharmaceutical sector[119]. Market and Industry Trends - The chemical industry accounted for 92.99% of total revenue, with revenue of ¥1,679,131,024.93, up 39.02% year-over-year[49]. - The demand for pharmaceutical intermediates in China is expected to increase annually due to the aging population, benefiting domestic companies in the pharmaceutical sector[116]. - The global pesticide market is expected to grow slowly, driven by increasing agricultural demand, which will positively impact China's pesticide intermediate industry[118]. - The pharmaceutical industry is experiencing a shift towards high-quality, innovative drugs, with a focus on complex processes and high technical difficulty[116]. Risks and Challenges - The company faces risks including macroeconomic fluctuations, industry risks, raw material price volatility, and exchange rate risks, which are detailed in the report[7]. - The company recognizes risks from macroeconomic fluctuations, particularly due to its significant export reliance, especially to the U.S.[123]. - The company will implement measures to manage foreign exchange risks due to its substantial export business[123]. Environmental Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities[171]. - The total wastewater discharge for COD was 4.254 tons per year, with a concentration of 186 mg/L, below the standard limit of 500 mg/L[171]. - The company reported a total nitrogen discharge of 0.095 tons per year, with a concentration of 8 mg/L, also below the standard limit[175]. - The company faced an administrative penalty of 800,000 yuan due to violations in wastewater discharge regulations[189]. - The company installed online monitoring facilities for wastewater discharge, ensuring compliance with environmental regulations[186]. Corporate Governance - The company is committed to ensuring the accuracy and completeness of its financial reports, as stated by its management team[6]. - The accounting firm engaged by the company is Dahua Certified Public Accountants (Special General Partnership)[20]. - The company has a dedicated investor relations team to handle inquiries and maintain communication with shareholders[17]. - The company has strictly fulfilled all commitments made by its actual controllers and shareholders during the reporting period[132]. - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[136].

Financial Performance - Net profit attributable to shareholders rose by 395.01% to CNY 43,583,641.68 for the reporting period[10] - Operating revenue for the period reached CNY 415,034,545.06, reflecting a 29.11% increase year-on-year[10] - Basic earnings per share increased by 175.61% to CNY 0.0452[10] - The weighted average return on net assets improved to 2.21%, up from 1.36% in the previous year[10] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 431.00% to CNY 41,679,811.74 for the reporting period[10] - The company reported a net profit margin of approximately 12.7% for Q3 2018, compared to 10.0% in Q3 2017[44] - The net profit attributable to the parent company was CNY 43,583,641.68, compared to CNY 8,804,644.99 in the previous year, marking an increase of about 393.5%[46] - The total profit for the third quarter reached CNY 57,771,201.60, compared to CNY 11,576,246.89 in the previous year, which is an increase of approximately 398.5%[45] - The total profit for the quarter was CNY 150,444,423.64, compared to CNY 62,516,146.80 in the same quarter last year, marking a significant increase[52] Revenue and Costs - Total operating revenue for the reporting period was 1.31426 billion yuan, an increase of 52.39% compared to the previous year, driven by significant growth in operating income and the addition of An'yang Aierwang Environmental Energy Co., Ltd.[23] - The total operating cost for the reporting period was 963.06 million yuan, an increase of 49.05% year-on-year, attributed to significant growth in operating costs and the addition of An'yang Aierwang Environmental Energy Co., Ltd.[24] - Total operating revenue for Q3 2018 reached CNY 415,034,545.06, an increase of 29.1% compared to CNY 321,463,797.23 in the same period last year[44] - Total operating costs for Q3 2018 were CNY 362,768,011.17, up 16.9% from CNY 310,087,142.86 in Q3 2017[44] Assets and Liabilities - Total assets increased by 9.51% to CNY 3,487,191,516.76 compared to the end of the previous year[10] - Non-current assets totaled CNY 1,811,026,650.95, an increase of 22.3% from CNY 1,481,080,607.10 at the beginning of the year[39] - The company's total liabilities amounted to CNY 1,385,723,691.08, reflecting a 12.5% increase from CNY 1,231,764,340.14[38] - The balance of long-term borrowings at the end of the period increased by 60.58 million yuan, a rise of 55.41%, mainly due to financing for increased project investments[22] - The balance of other current liabilities at the end of the period increased by 17.60 million yuan, a rise of 100%, primarily due to the addition of other current liabilities from An'yang Aierwang Environmental Energy Co., Ltd.[22] Shareholder Information - The company reported a total of 9,875 common shareholders at the end of the reporting period[14] - The largest shareholder, Alashankou Yabeng Investment Co., Ltd., holds 35.80% of the shares, with 293,350,646 shares pledged[14] - The company proposed a cash dividend of ¥0.6 per 10 shares for the 2017 fiscal year, with a total of 321,103,157 shares to be distributed, increasing the total share capital to 963,309,471 shares[30] - For the first half of 2018, a cash dividend of ¥0.4 per 10 shares was proposed, based on the total share capital of 963,309,471 shares[30] Cash Flow - Cash flow from operating activities decreased by 10.52% to CNY 188,043,705.05 year-to-date[10] - The net cash inflow from operating activities for the reporting period was 188.04 million yuan, a decrease of 22.11 million yuan compared to the same period last year, mainly due to increased cash payments for goods and services received[26] - The cash flow from operating activities was CNY 188,043,705.05, a decrease of 10.5% from CNY 210,143,853.69 in the previous year[60] - Operating cash inflow for the third quarter was CNY 217,553,407.94, an increase from CNY 105,734,303.30 in the previous year, reflecting a growth of approximately 105.5%[63] - Net cash flow from operating activities was CNY 18,169,455.54, a significant improvement compared to a net outflow of CNY -151,679,575.37 in the same period last year[64] Investment Activities - Total cash outflow from investment activities reached CNY 193,881,744.96, compared to CNY 28,172,969.58 in the previous year, indicating a substantial increase in investment spending[64] - Net cash flow from investment activities was CNY -179,141,465.52, worsening from CNY -21,172,114.88 year-over-year[64] Research and Development - Research and development expenses for the third quarter amounted to CNY 19,648,630.73, up from CNY 17,454,295.58, reflecting a year-over-year increase of approximately 12.6%[45] - Research and development expenses were CNY 8,575,808.00, down 30.4% from CNY 12,306,634.40 in the same period last year[55] Compliance and Governance - The company has committed to strict adherence to various promises made regarding share transfers and management practices, ensuring compliance with corporate governance standards[29] - There were no violations of external guarantees or non-operating fund occupation by controlling shareholders during the reporting period[31][32] - The company has maintained a consistent commitment to avoid competition with peers, ensuring strategic alignment among major shareholders[29] Miscellaneous - The report for the third quarter was not audited, which may affect the reliability of the financial data presented[66]

雅本化学股份有限公司 2018 年第三季度报告全文 公司负责人蔡彤、主管会计工作负责人李航及会计机构负责人(会计主管人 员)汤小新声明：保证季度报告中财务报表的真实、准确、完整。 雅本化学股份有限公司 2018 年第三季度报告 雅本化学 2018 年 10 月 1 雅本化学股份有限公司 2018 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 2 雅本化学股份有限公司 2018 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是√否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增 | | --- | --- | --- | --- | --- | | | | | | 减 | | 总资产（元） | 3,487,191,516.76 | | 3,184,229,174.08 | 9.51% | | 归属于上市公司股东的净资产 （元） | 1,9 ...

Financial Performance - Total revenue for the first half of 2018 reached ¥899,226,138.32, representing a 66.22% increase compared to ¥540,981,907.50 in the same period last year[17]. - Net profit attributable to shareholders was ¥76,462,202.12, an increase of 83.49% from ¥41,670,086.47 year-on-year[17]. - Net cash flow from operating activities was ¥286,379,408.61, up 118.11% from ¥131,301,869.18 in the previous year[17]. - Basic earnings per share increased to ¥0.0794, a 2.32% rise from ¥0.0776 in the same period last year[17]. - The company reported a net profit after deducting non-recurring gains and losses of ¥73,328,975.55, an increase of 80.60% from ¥40,601,951.41 year-on-year[17]. - Operating profit reached 93.30 million yuan, up 87.49% compared to the same period last year[35]. - The company reported a net profit of 13,237,448.3 CNY from its subsidiary Shanghai Yabont Chemical Co., Ltd. for the reporting period[63]. - The subsidiary Nantong Yabont Chemical Co., Ltd. generated a net profit of 45,941,450.3 CNY, contributing significantly to the overall performance[63]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,558,024,832.27, an increase of 11.74% from ¥3,184,229,174.08 at the end of the previous year[17]. - Total liabilities rose to CNY 1,511,553,700.02 from CNY 1,231,764,340.14, marking an increase of approximately 22.7%[134]. - Long-term borrowings increased to CNY 209,928,850.00 from CNY 109,333,031.87, indicating a rise of approximately 92%[134]. - The company reported a significant increase in goodwill, rising to CNY 359,398,695.45 from CNY 205,388,727.17, an increase of about 74.7%[133]. Cash Flow and Investments - The net cash flow from operating activities improved significantly by 118.11% to ¥286,379,408.61, attributed to accelerated fund recovery and the performance of subsidiaries not under common control[40]. - The company reported a net cash decrease of ¥-155,081,109.74, a 701.70% increase, due to increased project investments and reduced bank loans[40]. - Cash flow from financing activities resulted in a net outflow of CNY -23,119,266.50, a decrease from a net inflow of CNY 116,907,456.78 in the previous period, showing a shift in financing strategy[152]. - Cash paid for purchasing goods and services was CNY 479,274,150.45, an increase from CNY 325,400,301.64 in the previous period, indicating higher operational costs[150]. Research and Development - Research and development investment amounted to 49.42 million yuan, a 19.59% increase from the previous year[35]. - The company is focusing on enhancing its research and development capabilities to innovate and improve product offerings[165]. Market Position and Strategy - The company has established strategic partnerships with major players like DuPont, Bayer, and Roche, enhancing its market position[25]. - The company has expanded its production capacity while actively exploring new markets, particularly in the pesticide sector[36]. - The company is primarily engaged in high-end custom production for international agricultural and pharmaceutical giants, with a significant portion of its products being exported[67]. - The company anticipates that macroeconomic policy changes could impact its operations, particularly due to its reliance on exports[68]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of ¥0.4 per 10 shares, based on a total of 963,309,471 shares[6]. - The total cash dividend amounts to 38,532,378.84 yuan, which represents 100% of the distributable profit of 119,414,028.77 yuan[72]. - The total number of shareholders at the end of the reporting period was 9,551, with significant shareholders including a domestic non-state-owned enterprise holding 35.80%[114]. Environmental Management - Environmental management is a priority, with ongoing upgrades to pollution control measures to comply with national standards[68]. - The company has implemented measures to comply with environmental standards, with specific limits on COD, BOD, and SS emissions[95]. - The company has completed environmental impact assessments for all construction projects in compliance with legal regulations[102]. Corporate Governance - The company held two temporary shareholder meetings and one annual shareholder meeting during the reporting period, with participation rates of 35.81% and 0.24% respectively[71]. - The independent directors have expressed that the profit distribution plan complies with the company's actual situation and does not harm the interests of shareholders, especially minority shareholders[73]. - The company has not engaged in any major asset or equity sales during the reporting period[60]. Risks and Challenges - The company faces risks including macroeconomic fluctuations, environmental risks, management risks, and exchange rate risks[6]. - The company is focusing on optimizing its business structure and increasing domestic market development to mitigate potential risks[68].

Financial Performance - Total operating revenue for Q1 2018 reached ¥494,488,955.58, representing a 102.73% increase compared to ¥243,916,532.89 in the same period last year[8] - Net profit attributable to shareholders was ¥36,865,897.81, up 113.21% from ¥17,291,006.73 year-on-year[8] - Net profit excluding non-recurring gains and losses was ¥36,214,097.81, reflecting a 112.86% increase from ¥17,012,980.66 in the previous year[8] - The company's total revenue for the reporting period reached RMB 49,448.90 million, representing a year-on-year increase of 102.73%[19] - The net profit attributable to the parent company was RMB 3,686.59 million, an increase of 113.21% compared to the same period last year[20] - The total profit for the period was RMB 4,394.49 million, an increase of 101.91% compared to the previous year[21] - The net profit for the first quarter reached CNY 43,111,329.96, up from CNY 17,249,106.38 in the same period last year, reflecting a growth of approximately 150%[49] Cash Flow and Investments - Net cash flow from operating activities was ¥75,929,153.85, a 79.17% increase compared to ¥42,379,078.57 in the same period last year[8] - The total amount of raised funds is ¥109,989.28 million, with ¥28,274.57 million invested in the current quarter[29] - The total amount of raised funds utilized is CNY 53,669.66 million, with no changes in usage reported[30] - The company has invested CNY 7,840 million to acquire a 49% stake in Shanghai Puyi Chemical Technology Co., Ltd[30] - Cash payment for acquiring a 51% stake in Shanghai Puyi Chemical Technology Co., Ltd amounts to CNY 8,160 million, with a completion rate of 60%[30] - The cash outflow from investment activities totaled ¥627,120,850.89, compared to ¥32,812,474.32 in the previous period, indicating a substantial increase in investment expenditures[56] - The company reported a net cash flow from investment activities of -¥541,057,316.64, compared to -¥32,662,474.32 in the previous period, highlighting increased investment outflows[56] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,650,596,080.08, a 14.65% increase from ¥3,184,229,174.08 at the end of the previous year[8] - The company's inventory at the end of the period was RMB 49,726.28 million, up 69.10% year-on-year, primarily due to the consolidation of Aierwang's financial statements[19] - The total liabilities increased to CNY 1,445,446,627.31 from CNY 1,231,764,340.14, marking an increase of around 17.4%[41] - The company's equity attributable to shareholders reached CNY 3,286,659,971.32, compared to CNY 1,910,687,522.87 at the beginning of the year, reflecting a substantial increase of approximately 72%[42] Risks and Management - The company faces risks related to raw material price fluctuations, which could impact operating costs and profit margins[10] - Environmental risks are present due to the nature of the fine chemical industry, with increased costs expected for waste management compliance[11] - Management risks associated with rapid expansion are being addressed through the recruitment of management talent and training programs[11] Shareholder Commitments and Compliance - The company strictly fulfilled its commitments regarding share transfer limitations, ensuring that no more than 25% of the total convertible shares held can be transferred during the specified period[26] - The company has implemented measures to avoid conflicts of interest and ensure compliance with internal policies regarding the use of company assets[27] - All commitments made by the controlling shareholders and related parties have been fulfilled on time[27] - There are no overdue commitments from the actual controllers, shareholders, or related parties during the reporting period[26] Sales and Marketing - The company maintained strong customer demand, with a significant increase in orders driven by its competitive advantages in the pesticide intermediate customization industry[21] - The company reported a significant increase in sales expenses, which rose to RMB 2,091.69 million, a 311.34% increase year-on-year, mainly due to increased foreign exchange losses[19] - The company achieved a profit before tax of CNY 43,944,898.96, compared to CNY 21,764,876.43 in the previous year, marking a substantial improvement in profitability[48]